Description
The study shows RGS6-/- mice develop α-synuclein accumulation and identifies reduced cAMP signaling, but the molecular pathway connecting RGS6 loss to α-synuclein pathology remains unexplained. Understanding this mechanism is critical for therapeutic targeting.
Gap type: unexplained_observation Source paper: Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice. (2019, JCI Insight, PMID:31120439)
Resolution criteria
Resolution requires: (1) Pathway tracing: in RGS6-/- mice, phosphoproteomics of substantia nigra dopaminergic neurons (FACS-sorted TH+) identifies >=5 differentially phosphorylated proteins in the autophagy-lysosomal or ubiquitin-proteasome pathway (FDR<0.05) linking cAMP/PKA signaling reduction to alpha-syn clearance failure; (2) Rescue experiment: PKA activator (Forskolin 10 uM, 72h) or proteasome activator treatment of RGS6-/- dopaminergic neurons reduces pS129-alpha-syn puncta by >=40% vs. vehicle, confirming the cAMP-dependent pathway; (3) In vivo validation: viral rescue of RGS6 expression (AAV-TH-RGS6) in nigral neurons of RGS6-/- mice or adeno-associated PKA activation reduces alpha-syn aggregates by >=35% (quantified by ELISA or immunohistochemistry) and preserves dopaminergic neuron count. Phenotypic description of alpha-syn accumulation without mechanistic pathway validation is insufficient.